MedPath

Individualized Early Risk Assessment for Heart Diseases

Conditions
Cardiomyopathy, Hypertrophic
Cardiomyopathy, Dilated
Interventions
Other: Skin biopsy, genotyping and disease phenotyping
Registration Number
NCT02417311
Lead Sponsor
Universitätsklinikum Hamburg-Eppendorf
Brief Summary

Heart failure (HF) is the common end-stage of different medical conditions. It is the only growing cardiovascular disease and its prognosis remains worse than that of many malignancies. The lack of evidence-based treatment for patients with diastolic HF (HFpEF) exemplifies that the current "one for all" therapy has to be advanced by an individualized approach. Inherited cardiomyopathies can serve as paradigmatic examples of different HF pathogenesis. Both gain- and loss-of-function mutations of the same gene cause disease, calling for disease-specific agonism or antagonism of this gene´s function. However, mutations alone do not predict the severity of cardiomyopathies nor therapy, because their impact on cardiac myocyte function is modified by numerous factors, including the genetic context. Today, patient-specific cardiac myocytes can be evaluated by the induced pluripotent stem cell (hiPSC) technology. Yet, unfolding the true potential of this technology requires robust, quantitative, high content assays. The researchers' recently developed method to generate 3D-engineered heart tissue (EHT) from hiPSC provides an automated, high content analysis of heart muscle function and the response to stressors in the dish. The aim of this project is to make the technology a clinically applicable test. Major steps are (i) in depths clinical phenotyping and genotyping of patients with cardiomyopathies or HFpEF, (ii) follow-up of the clinical course, (iii) generation of hiPSC lines (40 patients, 40 healthy controls), and (iv) quantitative assessment of hiPSC-EHT function under basal conditions and in response to pro-arrhythmic or cardio-active drugs and chronic afterload enhancement. The product of this study is an SOP-based assay with standard values for hiPSC-EHT function/stress responses from healthy volunteers and patients with different heart diseases. The project could change clinical practice and be a step towards individualized risk prediction and therapy of HF.

Detailed Description

At present, heart function in patients can only be analysed by imaging methods or hemodynamic measurements. This has dramatically changed by the discovery that hiPSC can be generated from somatic cells (e.g. fibroblasts) by transduction of pluripotency genes. The investigators and others have shown that pluripotent stem cells can be efficiently differentiated into beating cardiac myocytes. This allows for the first time to study the function of cardiac myocytes from an individual patient. However, at present, only alterations were reproduced in hiPSC cells that were known previously and important limitations have to be resolved:

* Immaturity of hiPSC-derived cardiac myocytes

* Variability of hiPSC-generation, cardiac myocyte differentiation and experimental analyses

* No readout of contractile force, the parameter mostly affected in heart failure

* No modeling of hemodynamic stress in vitro

* No statistically valid correlation of hiPSC-cardiac myocyte function with clinical/genetic data

* Uncertainty as to standard values and adequate controls

* Unclear predictive value

The research challenge for the coming years is to resolve these shortcomings. IndivuHeart formulates a number of hypotheses and goals that are based on the researchers' longstanding expertise in tissue engineering and recent, still unpublished data on the pathophysiology of HCM and its modeling in EHT. The study will

* reveal standard values for hiPSC-EHT function in a statistically valid manner, both under basal and stress conditions,

* define a "cardiomyopathy phenotype" in vitro,

* allow new mechanistic insight into the pathogenesis of human HCM and DCM,

* uncover HCM-like abnormalities in HFpEF,

* allow individualized drug testing (acute and chronic).

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria
  • HCM: ProBNP ≥ 300 ng/l; IVSd ≥ 20 mm; E/E´ ≥ 8, LVOT > 30 mmHg
  • DCM: presence of signs and/or symptoms of HF (NYHA II-IV); ProBNP ≥ 300 ng/l; LV EF ≤ 40% for > 3 month
Exclusion Criteria
  • Uncontrolled hypertension,
  • coronary artery disease,
  • persistent atrial fibrillation,
  • enlisted for myectomy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
DCM patientsSkin biopsy, genotyping and disease phenotyping20 patients with dilated cardiomyopathy
Control groupSkin biopsy, genotyping and disease phenotyping40 healthy volunteers will serve as control group. Skin biopsy, genotyping and disease phenotyping
HCM patientsSkin biopsy, genotyping and disease phenotyping20 patients with hypertrophic cardiomyopathy
Primary Outcome Measures
NameTimeMethod
generation of hiPSC-EHT and in vitro phenotypingup to 60 month

After generation of proband-specific 3D-engineered heart tissue (EHT) from hiPSC we will make a quantitative assessment of hiPSC-EHT function under basal conditions and in response to pro-arrhythmic or cardio-active drugs and chronic afterload enhancement.

Secondary Outcome Measures
NameTimeMethod
clinical phenotyping and disease progressionup to 60 month

All 40 patients will be subjected to (i) high-end echocardiography including tissue Doppler and speckle tracking technology, (ii) MRI, (iii) spiroergometry and (iv) 24 h-holter ECG monitoring. Key parameters are guideline-recommended indices of systolic (e.g. fractional shortening, ejection fraction) and diastolic heart function (e.g. left atrial size, E/A, E'/A' and E/E´ratios), outflow tract gradient and cardiac remodeling (gadolinium late enhancement). The latter will be only done in HCM/DCM for ethical reasons. Technical analyses will be made at study entry and after 4 years, clinical examinations once a year (Cardiomyopathy Outpatient Clinic). Patients and their treating physicians will be prompted to report any clinical event during the course of the study.

genotypingup to 60 month

The genetic part of this project does not focus on the detection of new HCM/DCM disease genes, but on comprehensively determining the molecular basis of cardiomyopathy in the included patients. DNA samples will first be subjected to sequencing of a panel of about 120 cardiomyopathy-related candidate genes, which detects approximately 75% of all disease-causing mutations. The rest will be analysed by whole genome sequencing.

The resulting sequence data will be processed using CASAVA, followed by subsequent analyses using the GATK software package provided through the Broad Institute (Boston, USA) and the commercial software CLC-BIO.

Trial Locations

Locations (1)

Department of Experimental Pharmacology and Toxicology

🇩🇪

Hamburg, Germany

© Copyright 2025. All Rights Reserved by MedPath